Likewise, a monoclonal antibody that targets CD200 and prevents the ligand from binding to CD200R may effectively block the protein’s immunosuppressive signaling and restore the body’s protective defenses against tumor growth (51). This evidence concerns the gene CD200R1 and neoplasm.